OpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/23
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross ProceedsGlobeNewsWire • 10/12/23
OpGen Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
OpGen's Subsidiary Ares Genetics Releases New Features to its AREScloud OfferingGlobeNewsWire • 08/07/23
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern TimeGlobeNewsWire • 08/03/23
OpGen's Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FINDGlobeNewsWire • 07/19/23
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in EuropeGlobeNewsWire • 06/26/23
OpGen's Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 InstrumentsGlobeNewsWire • 06/22/23
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 ConferenceGlobeNewsWire • 06/20/23
OpGen Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/23
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern TimeGlobeNewsWire • 05/08/23
OpGen's Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FINDGlobeNewsWire • 04/26/23
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher HealthcareGlobeNewsWire • 04/18/23